542 related articles for article (PubMed ID: 33331201)
1. Adeno-associated virus (AAV) capsid engineering in liver-directed gene therapy.
Rodríguez-Márquez E; Meumann N; Büning H
Expert Opin Biol Ther; 2021 Jun; 21(6):749-766. PubMed ID: 33331201
[No Abstract] [Full Text] [Related]
2. Liver directed adeno-associated viral vectors to treat metabolic disease.
Chuecos MA; Lagor WR
J Inherit Metab Dis; 2024 Jan; 47(1):22-40. PubMed ID: 37254440
[TBL] [Abstract][Full Text] [Related]
3. Small But Increasingly Mighty: Latest Advances in AAV Vector Research, Design, and Evolution.
Grimm D; Büning H
Hum Gene Ther; 2017 Nov; 28(11):1075-1086. PubMed ID: 28835125
[TBL] [Abstract][Full Text] [Related]
4. Adeno-associated virus serotype 2 capsid variants for improved liver-directed gene therapy.
Meumann N; Cabanes-Creus M; Ertelt M; Navarro RG; Lucifora J; Yuan Q; Nien-Huber K; Abdelrahman A; Vu XK; Zhang L; Franke AC; Schmithals C; Piiper A; Vogt A; Gonzalez-Carmona M; Frueh JT; Ullrich E; Meuleman P; Talbot SR; Odenthal M; Ott M; Seifried E; Schoeder CT; Schwäble J; Lisowski L; Büning H
Hepatology; 2023 Mar; 77(3):802-815. PubMed ID: 35976053
[TBL] [Abstract][Full Text] [Related]
5. Chemical Modifications of the Capsid for Redirecting and Improving the Efficacy of Adeno-Associated Virus Vectors.
Lam AK; Frabutt D; Li L; Xiao W
Hum Gene Ther; 2021 Dec; 32(23-24):1433-1438. PubMed ID: 34254844
[TBL] [Abstract][Full Text] [Related]
6. Adeno-Associated Virus Vector Design-Moving the Adeno-Associated Virus to a Bioengineered Therapeutic Nanoparticle.
Jäschke N; Büning H
Hematol Oncol Clin North Am; 2022 Aug; 36(4):667-685. PubMed ID: 35778330
[TBL] [Abstract][Full Text] [Related]
7. Engineering and evolution of synthetic adeno-associated virus (AAV) gene therapy vectors via DNA family shuffling.
Kienle E; Senís E; Börner K; Niopek D; Wiedtke E; Grosse S; Grimm D
J Vis Exp; 2012 Apr; (62):. PubMed ID: 22491297
[TBL] [Abstract][Full Text] [Related]
8. Capsid Engineering Overcomes Barriers Toward Adeno-Associated Virus Vector-Mediated Transduction of Endothelial Cells.
Zhang L; Rossi A; Lange L; Meumann N; Koitzsch U; Christie K; Nesbit MA; Moore CBT; Hacker UT; Morgan M; Hoffmann D; Zengel J; Carette JE; Schambach A; Salvetti A; Odenthal M; Büning H
Hum Gene Ther; 2019 Oct; 30(10):1284-1296. PubMed ID: 31407607
[TBL] [Abstract][Full Text] [Related]
9. Vector Affinity and Receptor Distribution Define Tissue-Specific Targeting in an Engineered AAV Capsid.
Martino RA; Wang Q; Xu H; Hu G; Bell P; Arroyo EJ; Sims JJ; Wilson JM
J Virol; 2023 Jun; 97(6):e0017423. PubMed ID: 37199615
[TBL] [Abstract][Full Text] [Related]
10. Capsid-Engineering for Central Nervous System-Directed Gene Therapy with Adeno-Associated Virus Vectors.
Macdonald J; Marx J; Büning H
Hum Gene Ther; 2021 Oct; 32(19-20):1096-1119. PubMed ID: 34662226
[TBL] [Abstract][Full Text] [Related]
11. Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering.
Sen D
J Biomed Sci; 2014 Nov; 21(1):103. PubMed ID: 25425174
[TBL] [Abstract][Full Text] [Related]
12. Engineered Capsids for Efficient Gene Delivery to the Retina and Cornea.
Frederick A; Sullivan J; Liu L; Adamowicz M; Lukason M; Raymer J; Luo Z; Jin X; Rao KN; O'Riordan C
Hum Gene Ther; 2020 Jul; 31(13-14):756-774. PubMed ID: 32578442
[TBL] [Abstract][Full Text] [Related]
13. Boosters for adeno-associated virus (AAV) vector (r)evolution.
Szumska J; Grimm D
Cytotherapy; 2023 Mar; 25(3):254-260. PubMed ID: 35999132
[TBL] [Abstract][Full Text] [Related]
14. Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy.
Yang L; Li J; Xiao X
Methods Mol Biol; 2011; 709():127-39. PubMed ID: 21194025
[TBL] [Abstract][Full Text] [Related]
15. Adeno-associated virus serotypes: vector toolkit for human gene therapy.
Wu Z; Asokan A; Samulski RJ
Mol Ther; 2006 Sep; 14(3):316-27. PubMed ID: 16824801
[TBL] [Abstract][Full Text] [Related]
16. Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial.
Vandamme C; Adjali O; Mingozzi F
Hum Gene Ther; 2017 Nov; 28(11):1061-1074. PubMed ID: 28835127
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to AAV in clinical trials.
Mingozzi F; High KA
Curr Gene Ther; 2011 Aug; 11(4):321-30. PubMed ID: 21557723
[TBL] [Abstract][Full Text] [Related]
18. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells.
Martino AT; Basner-Tschakarjan E; Markusic DM; Finn JD; Hinderer C; Zhou S; Ostrov DA; Srivastava A; Ertl HC; Terhorst C; High KA; Mingozzi F; Herzog RW
Blood; 2013 Mar; 121(12):2224-33. PubMed ID: 23325831
[TBL] [Abstract][Full Text] [Related]
19. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them.
Hareendran S; Balakrishnan B; Sen D; Kumar S; Srivastava A; Jayandharan GR
Rev Med Virol; 2013 Nov; 23(6):399-413. PubMed ID: 24023004
[TBL] [Abstract][Full Text] [Related]
20. The role of the adeno-associated virus capsid in gene transfer.
Van Vliet KM; Blouin V; Brument N; Agbandje-McKenna M; Snyder RO
Methods Mol Biol; 2008; 437():51-91. PubMed ID: 18369962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
